169 related articles for article (PubMed ID: 21277463)
21. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
22. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.
Fakhraie G; Katz LJ; Prasad A; Eslami Y; Sabour S; Zarei R; Moghimi S
J Glaucoma; 2010 Mar; 19(3):212-8. PubMed ID: 19593201
[TBL] [Abstract][Full Text] [Related]
23. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
Güler M; Capkın M; Simşek A; Bilak S; Bilgin B; Hakim Reyhan A; Fırat M
Curr Eye Res; 2014 Oct; 39(10):989-93. PubMed ID: 24588314
[TBL] [Abstract][Full Text] [Related]
24. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents.
Pershing S; Bakri SJ; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(5):460-4. PubMed ID: 24044708
[TBL] [Abstract][Full Text] [Related]
25. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
26. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
[TBL] [Abstract][Full Text] [Related]
27. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections.
Skalicky SE; Ho I; Agar A; Bank A
Ophthalmic Surg Lasers Imaging; 2012 Jul; 43(4):328-34. PubMed ID: 22788585
[TBL] [Abstract][Full Text] [Related]
28. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report.
Sothornwit N
J Med Assoc Thai; 2008; 91 Suppl 1():S162-5. PubMed ID: 18672609
[TBL] [Abstract][Full Text] [Related]
30. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
Bakri SJ; Pulido JS; McCannel CA; Hodge DO; Diehl N; Hillemeier J
Eye (Lond); 2009 Jan; 23(1):181-5. PubMed ID: 17693999
[TBL] [Abstract][Full Text] [Related]
31. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection.
Im L; Allingham RR; Singh I; Stinnett S; Fekrat S
J Glaucoma; 2008 Mar; 17(2):128-32. PubMed ID: 18344759
[TBL] [Abstract][Full Text] [Related]
33. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
34. Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology.
Chung YR; Lee K; Cho EH; Lew HM
Eye (Lond); 2010 Aug; 24(8):1320-4. PubMed ID: 20379211
[TBL] [Abstract][Full Text] [Related]
35. Short-term intraocular pressure trends after intravitreal triamcinolone injection.
Lee EW; Hariprasad SM; Mieler WF; Newman TL; Apte RS
Am J Ophthalmol; 2007 Feb; 143(2):365-7. PubMed ID: 17258540
[TBL] [Abstract][Full Text] [Related]
36. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China.
Wang F; Yu S; Liu K; Chen FE; Song Z; Zhang X; Xu X; Sun X
Ophthalmology; 2013 Feb; 120(2):355-61. PubMed ID: 23084126
[TBL] [Abstract][Full Text] [Related]
37. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
Jonas JB; Degenring RF; Kreissig I; Akkoyun I; Kamppeter BA
Ophthalmology; 2005 Apr; 112(4):593-8. PubMed ID: 15808249
[TBL] [Abstract][Full Text] [Related]
38. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab.
Lee JW; Park H; Choi JH; Lee HJ; Moon SW; Kang JH; Kim YG
BMC Ophthalmol; 2016 May; 16():69. PubMed ID: 27245159
[TBL] [Abstract][Full Text] [Related]
39. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.
Gismondi M; Salati C; Salvetat ML; Zeppieri M; Brusini P
J Glaucoma; 2009 Dec; 18(9):658-61. PubMed ID: 20010243
[TBL] [Abstract][Full Text] [Related]
40. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma.
Agard E; Elchehab H; Ract-Madoux G; Russo A; Lagenaite C; Dot C
Can J Ophthalmol; 2015 Apr; 50(2):127-31. PubMed ID: 25863852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
